REFERENCES

1. Schluger NW. AJRCCM: 100-year anniversary. Focus on tuberculosis. Am J Respir Crit Care Med 2017;195:1112-4.

2. Schatz A, Bugie E, Waksman SA. The classic: streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria. Clin Orthop Relat Res 2005;437:3-6.

3. Hart PD. Chemotherapy of tuberculosis; research during the past 100 years. Br Med J 1946;2:805-10.

4. STREPTOMYCIN treatment of pulmonary tuberculosis. Br Med J 1948;2:769-82.

5. TREATMENT of pulmonary tuberculosis with isoniazid; an interim report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee. Br Med J 1952;2:735-46.

6. Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1972;1:1079-85.

7. Steele MA, Des Prez RM. The role of pyrazinamide in tuberculosis chemotherapy. Chest 1988;94:845-50.

8. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Third East African/British Medical Research Council Study. Tubercle 1980;61:59-69.

9. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. East and Central African/British Medical Research Council Fifth Collaborative Study. Tubercle 1986;67:5-15.

10. Dorman SE, Nahid P, Kurbatova EV, et al; AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med 2021;384:1705-18.

11. Turkova A, Wills GH, Wobudeya E, et al; SHINE Trial Team. Shorter treatment for nonsevere tuberculosis in African and Indian children. N Engl J Med 2022;386:911-22.

12. Paton NI, Cousins C, Suresh C, et al. Treatment strategy for rifampin-susceptible tuberculosis. N Engl J Med 2023;388:873-87.

13. Milstein M, Brzezinski A, Varaine F, Mitnick CD. (Re)moving the needle: prospects for all-oral treatment for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2016;20:18-23.

14. Gillespie SH, Crook AM, McHugh TD, et al; REMoxTB Consortium. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014;371:1577-87.

15. Jindani A, Harrison TS, Nunn AJ, et al; RIFAQUIN Trial Team. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014;371:1599-608.

16. Merle CS, Fielding K, Sow OB, et al; OFLOTUB/Gatifloxacin for Tuberculosis Project. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 2014;371:1588-98.

17. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012;380:986-93.

18. Tweed CD, Dawson R, Burger DA, et al. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomized, phase 2b trial. Lancet Respir Med 2019;7:1048-58.

19. Chen RY, Via LE, Dodd LE, et al; Predict TB Study Group. Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial. Gates Open Res 2017;1:9.

20. Lee A, Xie YL, Barry CE, Chen Y. Current and future treatments for tuberculosis. BMJ 2020;368:m216.

21. Dheda K, Gumbo T, Lange C, Horsburgh CR Jr, Furin J. Pan-tuberculosis regimens: an argument against. Lancet Respir Med 2018;6:240-2.

22. Efficacy and safety evaluation of two to four months of treatment with the combination regimens of DBOS and PBOS in adults with pulmonary tuberculosis. Bill & Melinda Gates Medical Research Institute (Responsible Party). 2023. Available from: https://clinicaltrials.gov/study/NCT05971602. [Last accessed on 26 Jun 2024].

23. Phase 2 trial assessing TBAJ876 or bedaquiline, with pretomanid and linezolid in adults with drug-sensitive pulmonary tuberculosis. Global Alliance for TB Drug Development (Responsible Party). 2023. Available from: https://clinicaltrials.gov/study/NCT06058299. [Last accessed on 26 Jun 2024].

24. Arboiser JL, Moschella SL. Clofazimine: a review of its medical uses and mechanisms of action. J Am Acad Dermatol 1995;32:241-7.

25. Lange C, Chesov D, Heyckendorf J. Clofazimine for the treatment of multidrug-resistant tuberculosis. Clin Microbiol Infect 2019;25:128-30.

26. Peloquin CA. Quinolones and tuberculosis. Ann Pharmacother 1996;30:1034-5.

27. Yew WW, Chan CK, Chau CH, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000;117:744-51.

28. Pablos-Mendez A, Gowda DK, Frieden TR. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework. Bull World Health Organ 2002;80:489-95.

29. World Health Organization. DOTS-Plus and the Green Light Committee. 2000. Available from: https://iris.who.int/handle/10665/66548. [Last accessed on 26 Jun 2024].

30. World Health Organization. Global tuberculosis report 2023. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023. [Last accessed on 26 Jun 2024].

31. Shah NS, Wright A, Bai GH, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007;13:380-7.

32. Seung KJ, Keshavjee S, Rich ML. Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med 2015;5:a17863.

33. Extensively drug-resistant tuberculosis---United States, 1993--2006. Morb Mortal Wkly Rep 2007;56:250-3. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5611a3.htm. [Last accessed on 26 Jun 2024]

34. Cobelens FGJ, Heldal E, Kimerling ME, et al; Working Group on MDR-TB of the Stop TB Partnership. Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda. PLoS Med 2008;5:e150.

35. Sotgiu G, Tiberi S, Centis R, et al. Applicability of the shorter “Bangladesh regimen” in high multidrug-resistant tuberculosis settings. Int J Infect Dis 2017;56:190-3.

36. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis - 2011 update. Available from: https://www.who.int/publications/i/item/9789241501583. [Last accessed on 26 Jun 2024].

37. Nunn AJ, Phillips PPJ, Meredith SK, et al; STREAM Study Collaborators. A trial of a shorter regimen for rifampin-resistant tuberculosis. N Engl J Med 2019;380:1201-13.

38. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR Recomm Rep 2013;62:1-12. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6209a1.htm. [Last accessed on 26 Jun 2024].

39. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis interim policy guidance. 2013. Available from: https://www.who.int/publications/i/item/9789241505482. [Last accessed on 26 Jun 2024].

40. Ryan NJ, Lo JH. Delamanid: first global approval. Drugs 2014;74:1041-5.

41. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. 2016. Available from: https://www.who.int/publications/i/item/9789241549639. [Last accessed on 26 Jun 2024].

42. Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment-2017; Ahmad N, Ahuja SD, Akkerman OW, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet 2018;392:821-34.

43. World Health Organization. WHO treatment guidelines for rifampicin- and multidrug-resistant tuberculosis, 2018 update. Guideline Development Group (GDG) meeting. Available from: https://www.who.int/news-room/events/detail/2018/07/16/default-calendar/who-treatment-guidelines-for-rifampicin--and-multidrug-resistant-tuberculosis-2018-update. [Last accessed on 26 Jun 2024].

44. Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis. an official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med 2019;200:e93-142.

45. Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med 2020;382:893-902.

46. Conradie F, Bagdasaryan TR, Borisov S, et al; ZeNix Trial Team. Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis. N Engl J Med 2022;387:810-23.

47. Goodall RL, Meredith SK, Nunn AJ, et al; STREAM study collaborators. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Lancet 2022;400:1858-68.

48. Nyang’Wa BT, Berry C, Kazounis E, et al; TB-PRACTECAL team. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial. Lancet Respir Med 2023;12:117-28.

49. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. Available from: https://www.who.int/publications/i/item/9789240063129. [Last accessed on 26 Jun 2024].

50. Landmark clinical trial redefines multidrug-resistant tuberculosis treatment options. Available from: https://endtb.org/endtb-clinical-trial-results. [Last accessed on 26 Jun 2024].

51. World Health Organization. Target regimen profiles for tuberculosis treatment, 2023 update. Available from: https://www.who.int/publications/i/item/9789240081512. [Last accessed on 26 Jun 2024].

52. Derksen JWG, May AM, Koopman M. The era of alternative designs to connect randomized clinical trials and real-world data. Nat Rev Clin Oncol 2019;16:589.

53. Fu L, Weng T, Sun F, et al. Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis. Int J Infect Dis 2021;111:138-47.

54. Fu L, Zhang X, Xiong J, et al. Selecting an appropriate all-oral short-course regimen for patients with multidrug-resistant or pre-extensive drug-resistant tuberculosis in China: a multicenter prospective cohort study. Int J Infect Dis 2023;135:101-8.

55. Efficacy and Safety of bedaquiline, delamanid, linezolid and moxifloxacin combination regimen for multidrug-resistant tuberculosis: a prospective two-arm cohort study. Shenzhen Third People’s Hospital. 2023. (in Chinese) Available from: https://www.chictr.org.cn/showproj.html?proj=186481. [Last accessed on 26 Jun 2024].

56. Padmapriyadarsini C, Vohra V, Bhatnagar A, et al; BEAT India Team. Bedaquiline, delamanid, linezolid and clofazimine for treatment of pre-extensively drug-resistant tuberculosis. Clin Infect Dis 2022;76:e938-46.